Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 44, 2018
Previous Article Next Article

Porphyrin–ferrocene conjugates for photodynamic and chemodynamic therapy

Author affiliations


Chemodynamic therapy can convert endogenous hydrogen peroxide (H2O2) at tumor localization into the toxic hydroxyl radical (˙OH) destroying tumor cells. Photodynamic therapy as a noninvasive method utilizes photosensitizers (PSs) to convert O2 into cytotoxic reactive oxygen species (e.g., 1O2) upon laser irradiation, which is dependent on the content of oxygen. The combination of the two therapeutic strategies on a single platform can enhance the anticancer effect. Herein, we report a porphyrin–ferrocene theranostic agent for combined photodynamic and chemodynamic therapy. Compared to monotherapy, the as-prepared porphyrin–ferrocene conjugates exhibit superior efficiency and potency in killing cancer cells at low drug doses. This study suggests the rational design of molecular structures as multifunctional therapeutics for potential clinic application.

Graphical abstract: Porphyrin–ferrocene conjugates for photodynamic and chemodynamic therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 26 Sep 2018, accepted on 25 Oct 2018 and first published on 25 Oct 2018

Article type: Paper
DOI: 10.1039/C8OB02391C
Org. Biomol. Chem., 2018,16, 8613-8619

  •   Request permissions

    Porphyrin–ferrocene conjugates for photodynamic and chemodynamic therapy

    Z. Lei, X. Zhang, X. Zheng, S. Liu and Z. Xie, Org. Biomol. Chem., 2018, 16, 8613
    DOI: 10.1039/C8OB02391C

Search articles by author